Thyroid Disorders in Women: Hypothyroidism, Hyperthyroidism, and More

Thyroid disorders affect women at a rate approximately 5 to 8 times higher than men, according to the American Thyroid Association, making thyroid dysfunction one of the most prevalent endocrine conditions in women's health. This page covers the two primary categories — hypothyroidism and hyperthyroidism — along with structural thyroid conditions such as nodules, goiter, and thyroiditis, explaining how each condition works, how they differ, and what factors influence clinical decision-making. Understanding thyroid function is central to broader hormonal health, including reproductive outcomes, bone density, and cardiovascular risk — areas explored across the Women's Health Authority resource index.

Definition and scope

The thyroid gland, a butterfly-shaped structure at the base of the neck, produces triiodothyronine (T3) and thyroxine (T4), hormones that regulate metabolism, body temperature, heart rate, and organ function. Thyroid-stimulating hormone (TSH), secreted by the pituitary gland, governs T3 and T4 output through a feedback loop. When that loop is disrupted, systemic effects follow.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) classifies thyroid disorders into functional and structural categories:

Functional disorders involve abnormal hormone output:
- Hypothyroidism — insufficient thyroid hormone production
- Hyperthyroidism — excessive thyroid hormone production
- Subclinical thyroid dysfunction — abnormal TSH with normal T3/T4 levels

Structural disorders involve physical changes to gland tissue:
- Goiter — diffuse or nodular gland enlargement
- Thyroid nodules — focal growths, the majority of which are benign
- Thyroiditis — inflammation, encompassing Hashimoto's, postpartum, and subacute forms

Thyroid cancer, while less common, is also disproportionately diagnosed in women; the American Cancer Society estimates women account for roughly 3 out of every 4 thyroid cancer diagnoses annually in the United States.

The regulatory and clinical framework governing thyroid care in the US is shaped by the U.S. Preventive Services Task Force (USPSTF) and professional guidelines from the American Thyroid Association. The broader landscape of regulatory expectations for women's health conditions is detailed at Regulatory Context for Women's Health.

How it works

Hypothyroidism: underactive thyroid

In hypothyroidism, the thyroid produces insufficient T3 and T4. The pituitary compensates by releasing more TSH, producing the elevated TSH reading characteristic of primary hypothyroidism. The most common cause in the United States is Hashimoto's thyroiditis, an autoimmune condition in which immune cells attack thyroid tissue. Hashimoto's affects an estimated 14 million Americans, with women comprising the large majority of cases (NIDDK).

Symptoms of hypothyroidism include:
1. Fatigue and sluggishness
2. Weight gain despite unchanged caloric intake
3. Cold intolerance
4. Dry skin, brittle nails, and hair thinning
5. Constipation
6. Cognitive slowing ("brain fog")
7. Menstrual irregularities, including heavy or infrequent periods
8. Depression

Diagnosis rests primarily on serum TSH measurement. A TSH above the laboratory reference range (typically above 4.0–5.0 mIU/L, depending on the assay) with low free T4 confirms overt hypothyroidism. Treatment is standardized: levothyroxine (synthetic T4) taken orally, with dosing titrated to normalize TSH levels.

Hyperthyroidism: overactive thyroid

In hyperthyroidism, excess thyroid hormone suppresses TSH to below-normal levels. The most common cause is Graves' disease, an autoimmune condition producing antibodies (TSH receptor antibodies, or TRAb) that continuously stimulate thyroid hormone output. Other causes include toxic multinodular goiter and toxic adenoma.

Symptoms of hyperthyroidism include:
1. Unintentional weight loss
2. Rapid or irregular heartbeat (palpitations, atrial fibrillation)
3. Heat intolerance and excessive sweating
4. Tremor
5. Anxiety and irritability
6. Sleep disturbance
7. Frequent bowel movements
8. Menstrual irregularities, often lighter or absent periods

Treatment options for hyperthyroidism include antithyroid medications (methimazole, propylthiouracil), radioactive iodine ablation, and thyroidectomy. Each carries distinct risk profiles; choice depends on disease severity, pregnancy status, and patient factors as evaluated by an endocrinologist.

Hypothyroidism vs. hyperthyroidism: key contrasts

Common scenarios

Thyroid dysfunction in pregnancy: Both untreated hypothyroidism and hyperthyroidism carry documented risks in pregnancy, including preeclampsia, preterm birth, and fetal developmental effects. The American Thyroid Association's 2017 guidelines on thyroid disease in pregnancy establish trimester-specific TSH reference ranges and recommend universal screening discussion for high-risk pregnancies (ATA Guidelines, Thyroid 2017).

Postpartum thyroiditis: An estimated 5–10% of women develop postpartum thyroiditis within the first year after delivery, per NIDDK. This condition typically follows a biphasic course — an initial hyperthyroid phase followed by a hypothyroid phase — before resolving. A subset of affected women develop permanent hypothyroidism.

Subclinical hypothyroidism: Defined as elevated TSH with normal free T4, this finding affects an estimated 3–8% of the general population, with higher prevalence in older women. Whether to treat subclinical hypothyroidism remains debated; the USPSTF concluded in its 2015 review that evidence was insufficient to recommend universal screening in asymptomatic adults.

Thyroid nodules: Nodules are detected in up to 50% of the adult population on high-resolution ultrasound, most incidentally. The American Thyroid Association's 2015 nodule management guidelines stratify risk by ultrasound pattern, size, and clinical context to determine whether fine-needle aspiration biopsy is warranted.

Thyroid dysfunction and autoimmune overlap: Women with autoimmune conditions — lupus, rheumatoid arthritis, or type 1 diabetes — carry elevated risk for co-occurring Hashimoto's disease. This intersection is relevant for patients also reviewed under Autoimmune Conditions in Women.

Decision boundaries

Clinical decision-making in thyroid disorders hinges on several structured thresholds:

Diagnosis thresholds:
- Overt hypothyroidism: TSH above reference range + low free T4
- Subclinical hypothyroidism: TSH above reference range + normal free T4
- Overt hyperthyroidism: TSH below reference range + elevated free T4 and/or free T3
- Subclinical hyperthyroidism: TSH below reference range + normal free T4 and free T3

Treatment initiation:
- Levothyroxine is generally indicated for overt hypothyroidism and for subclinical hypothyroidism in pregnancy
- Subclinical hypothyroidism in non-pregnant adults with TSH below 10 mIU/L: clinical guidelines (ATA, AACE) indicate that treatment decisions are individualized, considering symptom burden, age, and cardiovascular risk
- Antithyroid therapy initiation for hyperthyroidism depends on degree of TSH suppression, symptom severity, and contraindications

Monitoring parameters:
- After initiating levothyroxine, TSH is typically rechecked at 6–8 weeks; once stable, annual monitoring is standard
- Free T4 and T3 levels are checked alongside TSH when clinical presentation diverges from TSH alone

Screening recommendations:
- The USPSTF does not currently recommend routine thyroid screening in asymptomatic adults
- The American Thyroid Association recommends clinician-patient discussion of screening beginning at age 35, repeated every 5 years
- Screening is recommended for high-risk groups: family history of thyroid disease, prior head/neck radiation, autoimmune conditions, or symptoms consistent with thyroid dysfunction

Structural lesion boundaries:
- Nodules ≥1 cm with high-suspicion ultrasound features require fine-needle aspiration per ATA 2015 nodule guidelines
- Nodules <0.5 cm generally do not require biopsy regardless

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)